SCHEMBL202998

SCHEMBL202998

c1ccc2c(c1)ncc1nc3n(c12)OCCCC3

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
HSD17B10 Q99714 2/20 0.37
USP2 O75604 1/20 0.37
CYP1A2 P05177 1/20 0.37
BCHE P06276 1/20 0.37
CFTR P13569 1/20 0.37
ALOX15 P16050 1/20 0.37
ACHE P22303 1/20 0.37
HKDC1 Q2TB90 1/20 0.37
GOPC Q9HD26 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GPR3 P46089 1/20 0.36
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL202424 0.96 KDM4E (0.38) MEN1KMT2AHDAC6KDM4EALDH1A1
SCHEMBL204000 0.90 KDM4E (0.39) MEN1KMT2AHDAC6KDM4EALDH1A1
SCHEMBL202353 0.76 TLR7 (0.41) LMNA
SCHEMBL10123167 0.70 KDM4E (0.43) MEN1KMT2AHDAC6KDM4EALDH1A1
SCHEMBL202473 0.66 ALDH1A1 (0.36) KDM4EALDH1A1GPR3LMNASMN1; SMN2
SCHEMBL205008 0.66 KDM4E (0.37) MEN1KMT2AKDM4EALDH1A1HSD17B10
SCHEMBL202499 0.66 TLR7 (0.44) LMNA
SCHEMBL4593950 0.65 ALDH1A1 (0.54) MEN1KMT2AHDAC6KDM4EALDH1A1
SCHEMBL12888417 0.65 NCF1 (0.43) MEN1KMT2AHDAC6KDM4EALDH1A1
SCHEMBL12020770 0.64 KDM4E (0.33) KDM4EALDH1A1HSD17B10GPR3GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088788-B2 Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-03 US disclosed
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS PFIZER INC. 2009-09-03 US disclosed
WO-2007106852-A2 SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS IL2, IFNG, IL4 MEN1 4112/4885KMT2A 3293/4885HDAC6 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.